Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 7:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 132 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Timolol Clear all
Recruiting Phase 4 Interventional Accepts healthy volunteers

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

NCT06883123
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
Prairie Eye Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 18, 2026, 7:31 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

NCT02097719
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
bimatoprost 0.01%, travoprost 0.004%, timolol 0.5%, hypromellose 0.3%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Racine, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 18, 2026, 7:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and IOP-Lowering Effects of WB007

NCT04149899
View directory record Official record
Conditions
Glaucoma, Primary Open Angle, Ocular Hypertension
Interventions
WB007 0.05%, WB007 0.15%, WB007 0.4%, Timolol 0.5%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 18, 2026, 7:31 AM EDT
Terminated Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma

NCT01426113
View directory record Official record
Conditions
Glaucoma
Interventions
bimatoprost ophthalmic solution formulation A, timolol ophthalmic solution, bimatoprost vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
2 Months to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 18, 2026, 7:31 AM EDT
Completed Phase 4 Interventional Results available

Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions

NCT00906087
View directory record Official record
Conditions
Glaucoma
Interventions
Cosopt (combination eyedrop of dorzolamide and timolol)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 18, 2026, 7:31 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

NCT00652106
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution, Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution, Brimonidine 0.2% ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 18, 2026, 7:31 AM EDT
Not listed Not applicable Interventional

Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.

NCT00440336
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Cosopt, Xalatan
Drug
Lead sponsor
Advanced Glaucoma Specialists
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Reading, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2007 · Synced Oct 18, 2026, 7:31 AM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

NCT02730871
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 18, 2026, 7:31 AM EDT
Completed Phase 3 Interventional Results available

Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT01749904
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
BOL-303259-X, Timolol
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 18, 2026, 7:31 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes

NCT03579160
View directory record Official record
Conditions
Wound of Skin, Wound Heal, Surgical Wound, Full Thickness Skin Graft Healing
Interventions
0.25% timolol gel with full-thickness skin grafts, Vaseline dressing
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 18, 2026, 7:31 AM EDT
Completed Phase 2 Interventional Results available

SYL040012, Treatment for Open Angle Glaucoma

NCT02250612
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran), 1 drop of 1.5% SYL040012 (bamosiran), 1 drop of 0.5 % timolol maleate
Drug
Lead sponsor
Sylentis, S.A.
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Artesia, California • Petaluma, California • Morrow, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 18, 2026, 7:31 AM EDT
Terminated Early Phase 1 Interventional Results available

Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas

NCT01147601
View directory record Official record
Conditions
Hemangioma, Infant
Interventions
topical 0.5% Timolol, Control (placebo) group
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
1 Month to 8 Months
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Oct 18, 2026, 7:31 AM EDT
Completed Phase 3 Interventional

Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients

NCT00651612
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution, Concurrent brimonidine 0.2% and 0.5% timolol
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 18, 2026, 7:31 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

NCT00332540
View directory record Official record
Conditions
Ocular Hypertension
Interventions
bimatoprost/timolol fixed combination
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 18, 2026, 7:31 AM EDT
Completed No phase listed Observational

YouScript IMPACT Registry

NCT02191358
View directory record Official record
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Not listed
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 18, 2026, 7:31 AM EDT
Completed No phase listed Observational Results available

A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs

NCT00823043
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
timolol hemihydrate, timolol maleate
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 18, 2026, 7:31 AM EDT
Completed Phase 1 Interventional

Timolol for the Treatment of Acne and Rosacea

NCT02774590
View directory record Official record
Conditions
Acne Vulgaris, Rosacea
Interventions
Timolol
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 18, 2026, 7:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ontogeny of Infantile Hemangiomas With Skin Imaging Modalities

NCT02061735
View directory record Official record
Conditions
Infantile Hemangiomas
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Month to 5 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 18, 2026, 7:31 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Comparison of Latanoprost Vs. Timolol

NCT00579969
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost, Timolol
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 18, 2026, 7:31 AM EDT
Completed Phase 2 Interventional

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01917383
View directory record Official record
Conditions
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
Trabodenoson, Latanoprost, Timolol
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bristol, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 18, 2026, 7:31 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

NCT00332059
View directory record Official record
Conditions
Ocular Hypertension
Interventions
bimatoprost/timolol fixed combination
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bel Air, Maryland
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 18, 2026, 7:31 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

NCT03691662
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
12 Months and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
34
States / cities
Chandler, Arizona • Prescott, Arizona • Glendale, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 18, 2026, 7:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)

NCT00698945
View directory record Official record
Conditions
Ocular Hypertension, Open-Angle Glaucoma
Interventions
Istalol and Optive, Alphagan
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Petaluma, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2008 · Synced Oct 18, 2026, 7:31 AM EDT
Completed Phase 2 Interventional Results available

Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.

NCT02571972
View directory record Official record
Conditions
Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Dorzolamide-timolol
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 18, 2026, 7:31 AM EDT